Braveheart Bio director buys 55,555 shares at $18
Braveheart Bio, Inc. director David Charles Lubner reported acquiring equity in two ways.
Rhea-AI Filing Summary
Braveheart Bio, Inc. director David Charles Lubner reported acquiring equity in two ways. On 2026-08-07, he purchased 55,555 shares of Common Stock at $18.00 per share in a direct open-market or private transaction, bringing his directly held common shares to 55,555. On 2026-08-05, he also received a grant of stock options for 60,000 shares of Common Stock with an exercise price of $18.00 per share, expiring on 2036-08-04. According to the grant terms, 1/36 of the option vests in substantially equal monthly installments on each monthly anniversary of July 23, 2026, contingent on his continuous service to the company.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 55,555 shares
Net Buy
2 txns
Insider
Lubner David Charles
Role
Director
Bought
55,555 shs ($1000K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 55,555 | $18.00 | $1000K |
| Grant/Award | Stock Option (Right to Buy) F1 | 60,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct);
Common Stock — 55,555 shares (Direct)
Footnotes (1)
- F1. 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Common shares purchased: 55,555 shares
Purchase price per share: $18.00
Common shares held after purchase: 55,555 shares
+4 more
7 metrics
Common shares purchased
55,555 shares
Direct purchase of Braveheart Bio common stock on 2026-08-07
Purchase price per share
$18.00
Price paid for each common share in the 2026-08-07 transaction
Common shares held after purchase
55,555 shares
Director’s direct common stock holdings following the reported purchase
Stock options granted
60,000 options
Options for Braveheart Bio common stock granted on 2026-08-05
Option exercise price
$18.00
Exercise price per share for the 60,000 stock options
Option expiration date
2036-08-04
Expiration of the 60,000 stock options granted to the director
Vesting commencement reference date
July 23, 2026
Monthly vesting installments begin based on this date, in 1/36 increments
Key Terms
Stock Option (Right to Buy), exercise price, vest and become exercisable, continuous service
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "18.0000" as the option exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"1/36th of the shares subject to such option vest and become exercisable"
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Braveheart Bio (BRVE) director David Charles Lubner buy in this Form 4?
David Charles Lubner purchased 55,555 shares of Braveheart Bio common stock at $18.00 per share on 2026-08-07. The transaction was reported as a direct open-market or private purchase, and he held 55,555 common shares afterward.
What stock options were granted to the BRVE director in this filing?
On 2026-08-05, David Charles Lubner received a grant of 60,000 stock options for Braveheart Bio common stock with an exercise price of $18.00 per share. The options expire on 2036-08-04, providing a 10-year term from grant.
How do the Braveheart Bio (BRVE) options granted to the director vest?
The 60,000 Braveheart Bio stock options vest over time. According to the terms, 1/36 of the shares vest in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to his continuous service.
Is the Braveheart Bio (BRVE) director’s stock option grant an open-market purchase?
No. The 60,000 Braveheart Bio stock options were reported as a grant or award with an exercise price of $18.00 per share. Separately, he conducted an open-market or private purchase of 55,555 common shares at $18.00 per share.
What is the combined scale of Braveheart Bio (BRVE) equity acquired by the director?
David Charles Lubner reported an outright purchase of 55,555 common shares plus a grant of 60,000 stock options exercisable into common stock at $18.00 per share, indicating both immediate ownership and additional potential future equity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
